Up-Front and Milestone Payments. As a part of consideration for the patent assignment and license grant by TAKEDA hereunder, TOBIRA shall make the following milestone payments to TAKEDA, each of which shall be due [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. once only upon occurrence of the following respective trigger events, and payable in US Dollars pursuant to the following instalments within (a) thirty (30) days after the respective trigger event with regard to instalments i. to vi. below; and (b) only with regard to the instalments under the following vii. to ix., within sixty (60) days after the end of the first calendar year in which [*] Trigger Event Milestone Payment [*] [*] [*] For the avoidance of doubt, (i) should it become clear that the [*] the relevant milestone payment corresponding to [*] mentioned above, as the case may be, shall be due at the time when such fact becomes clear, and, even if such fact does not become clear, such payment shall be due at the latest, together with the immediately following milestone payment, upon occurrence of such the immediately following trigger event, and (ii) each milestone shall be payable only once at the first achievement of the relevant milestone event and TOBIRA shall not be required to make the milestone payments for the Product(s) containing the Reserve Compound (hereinafter called the “Reserve Product”) for the same trigger events for which TOBIRA had already made such milestone payments with regard to the Product(s) containing the Principal Compound (hereinafter called the “Principal Product”), if any, and vice versa, as stipulated in Article 6.B.
Up-Front and Milestone Payments. Subject to the terms and conditions of this Agreement, Guidant shall make the following payments:
Up-Front and Milestone Payments. For the avoidance of doubt, in the event that Cerus receives any up-front, milestone, license fee or similar payments (collectively “Lump Sum Payments”) from any sublicensee, collaborator or partner in connection with the granting of any development, marketing, distribution or other rights under this Agreement, Cerus [ * ]. Notwithstanding the foregoing, in the event that (a) rights revert from BioOne to Baxter and Cerus in Japan and/or China as to the Platelet System, and (b) within [ * ] months of the date of such reversion, Cerus enters into a license agreement with a third party for commercialization of the Platelet System in Japan or China, as the case may be, then Cerus shall pay to Baxter [ * ] of any lump sum Payments that are received by Cerus from the third party for such license and that relate to such countries. Lump sum payments shall not be considered to include any funds paid to Cerus specifically for development or support activities relating to commercialization of the Platelet System or any equity investment in Cerus.
Up-Front and Milestone Payments. In consideration of the Assets sold and other rights granted to IPC by Sobi hereunder and subject to the terms and conditions of this Agreement, IPC shall make the following payments to Sobi:
Up-Front and Milestone Payments. As consideration to Indevus for the rights granted to Orion hereunder, Orion shall make the following payments to Indevus:
Up-Front and Milestone Payments. CONFORMA shall pay to SUMITOMO, up to a total amount of [***] US Dollars (US$ [***]) within thirty (30) days after the first occurrence of the following events: [Events] [Payments]
Up-Front and Milestone Payments. In consideration of the exclusive rights to manufacture and supply granted to PCD under the terms and conditions set forth in this Agreement including but not limited to Article 2.5, PCD shall pay SPI a total of $3 million according to the following schedule. EVENT PAYMENT On Execution of this Agreement $1 million Upon commencement of the first Phase II trial for Irritable Bowel Syndrome $2 million
Up-Front and Milestone Payments. In consideration of the exclusive rights to manufacture and supply granted to RTU under the terms and conditions set forth in this Agreement including but not limited to Article 2.5, RTU shall pay SPL a total of $1 million (within a consumption tax) according to the following schedule. EVENT PAYMENT On Execution of this Agreement $0.25 million NDA approval in Japan $ 0.5 million At beginning of commercial launch in Japan $0.25 million
Up-Front and Milestone Payments. 11.01 In consideration of and exchange for the exclusive rights granted to ISTA under this Agreement, and subject to the terms hereof, ISTA shall, during the term of this Agreement, pay TANABE the upfront payment and development milestone payments for Single Product, Steroid Combination Product and Multiple API Combination Product as follows: Up Front Payment Event: Amount of Payment: [ * ] [ * ] Development Milestone Payments Single Product: Event: Amount of Payment: [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] Steroid Combination Product: Event: Amount of Payment: [ * ] [ * ] [ * ] [ * ] Multiple API Combination Product Event: Amount of Payment: [ * ] [ * ] [ * ] [ * ]
Up-Front and Milestone Payments
